Lipitor Sales Plummet 13 Percent In Q2 On Inventory Fluctuations, Generic Pressure
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer also reports 48 percent drop in earnings due to patent losses, upfront payment to Bristol for anticoagulant apixaban deal.
You may also be interested in...
Pfizer Lipitor Patent Fails PTO Reexamination
In an initial office action, the U.S. Patent and Trademark Office rejects the claims in Lipitor’s basic patent.
Pfizer Lipitor Patent Fails PTO Reexamination
In an initial office action, the U.S. Patent and Trademark Office rejects the claims in Lipitor’s basic patent.
Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.